Within the baricitinib group, patients experienced a mean Vitiligo Area Scoring Index score change of 44.8% from baseline to week 36. In contrast, the placebo group saw a 9.2% change. The Janus ...

Baricitinib can effectively treat polymyalgia rheumatica (PMR) without the use of oral glucocorticoids, according to results from a small, randomized, double-blind, placebo-controlled study.

Baricitinib, a Janus kinase (JAK) inhibitor, combined with narrowband ultraviolet B (UVB) phototherapy, reduced disease activity and improved repigmentation and quality of life in adults with ...

For the last year, he had been treated for atopic dermatitis with the Janus kinase (JAK) inhibitor baricitinib, which blocks the type I interferon signaling pathway, at a dose of 4 mg/day.